Market: NASD |
Currency: USD
Address: Building 14
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
📈 Greenwich LifeSciences, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$45.00
-
Upside/Downside from Analyst Target:
279.75%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Greenwich LifeSciences, Inc.
| Date | Reported EPS |
|---|
| 2025-08-14 | -0.3 |
| 2025-05-20 | -0.25 |
| 2025-04-15 | -0.61 |
| 2024-11-14 | -0.2 |
| 2024-08-14 | -0.2 |
| 2024-05-20 | -0.19 |
| 2024-04-15 | -0.21 |
| 2023-10-19 | -0.19 |
| 2023-08-21 | -0.13 |
| 2023-05-22 | -0.17 |
| 2023-03-31 | -0.22 |
| 2022-11-14 | -0.18 |
| 2022-08-15 | -0.06 |
| 2022-05-20 | -0.15 |
| 2022-03-21 | -0.18 |
| 2021-11-15 | -0.07 |
| 2021-08-13 | -0.06 |
| 2021-05-20 | -0.05 |
| 2021-03-31 | -0.12 |
📰 Related News & Research
No related articles found for "greenwich lifesciences".
